Please login to the form below

Not currently logged in
Email:
Password:

triglycerides

This page shows the latest triglycerides news and features for those working in and with pharma, biotech and healthcare.

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

Epanova was acquired by AZ in its $443m takeover of Omthera in 2013, and was approved in 2014 as an adjunct to diet to reduce triglyceride levels in adults with severe

Latest news

More from news
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    aureus and Shigellosis. Corporate acquisition. 190. Amarin/ Eddingpharm. VASCEPA (icosapent ethyl) - triglyceride level reduction.

  • Pharma deals during May 2014 Pharma deals during May 2014

    One year ago AstraZeneca acquired Omthera. On May 7 Epanova, a soft gelation capsule containing Omega-3, was approved by the FDA as an adjunct to diet to reduce triglyceride levels

  • Pharma deals during November 2012 Pharma deals during November 2012

    a cash buyout valued at $845m. Pronova supplies the active ingredient in GSK's triglyceride lowering omega-3 drug Lovaza and, in addition, is developing competitor formulations – the most advanced being

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Channel purpose, change lives

    Ideas came to life through a multitude of means, from AstraZeneca’s talking fish who discuss "love, life and triglycerides" to Cancer Council NSW’s ‘I Touch Myself Project’ that reinvented

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics